In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Glaukos (GKOS – Research Report), with a price target of ...

In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

According to BTIG Research, value stocks are closing at a 40-year low relative to growth. The primary reason is that ...

Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of ...

BTIG Research has recently reduced Vuzix Corp (VUZI) stock to Neutral rating, as announced on November 10, 2023, according to Finviz. Earlier, on December 21, 2021, Dawson James had initiated the ...

BTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names ...

BTIG Chief Market Technician Jonathan Krinsky thinks the market can “continue to make upside progress” into year-end and sees a new all-time high for the S&P 500 (SPX) above 6,100. However ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...